Salvage lenalidomide in four rare oncological diseases

J 2013

Salvage lenalidomide in four rare oncological diseases

SZTURZ, Petr, Zdeněk ADAM, Zdenek REHAK, Renata KOUKALOVÁ, Leoš KŘEN et. al.

Basic information

Original name

Salvage lenalidomide in four rare oncological diseases

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Zdenek REHAK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Leoš KŘEN (203 Czech Republic), Mojmír MOULIS (203 Czech Republic), Marta KREJČÍ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Tumori, Roma, PENSIERO SCIENTIFICO EDITOR, 2013, 0300-8916

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.090

RIV identification code

RIV/00216224:14110/13:00065660

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1700/1377.15326

Keywords in English

Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease

Abstract

V originále

In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.

Links

MSM0021622434, plan (intention)

Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

MUNI/A/0723/2012, interní kód MU

Name: Nové klinické a diagnostické přístupy u hematogických malignit (Acronym: NoKliDiPřiHeMa)

Investor: Masaryk University, Category A

NT13190, research and development project

Name: Molekulární charakteristika centrozomálních abnormalit a jejich prognostický význam pro pacienty s mnohočetným myelomem

Investor: Ministry of Health of the CR

Citovat

SZTURZ, Petr, Zdeněk ADAM, Zdenek REHAK, Renata KOUKALOVÁ, Leoš KŘEN, Mojmír MOULIS, Marta KREJČÍ and Jiří MAYER. Salvage lenalidomide in four rare oncological diseases. Tumori. Roma: PENSIERO SCIENTIFICO EDITOR, 2013, vol. 99, No 5, p. "e251"-"e256", 6 pp. ISSN 0300-8916. Available from: https://dx.doi.org/10.1700/1377.15326.

@article{1159188,
   author = {Szturz, Petr and Adam, Zdeněk and Rehak, Zdenek and Koukalová, Renata and Křen, Leoš and Moulis, Mojmír and Krejčí, Marta and Mayer, Jiří},
   article_location = {Roma},
   article_number = {5},
   doi = {http://dx.doi.org/10.1700/1377.15326},
   keywords = {Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease},
   language = {eng},
   issn = {0300-8916},
   journal = {Tumori},
   title = {Salvage lenalidomide in four rare oncological diseases},
   url = {http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326},
   volume = {99},
   year = {2013}
}

TY  - JOUR
ID  - 1159188
AU  - Szturz, Petr - Adam, Zdeněk - Rehak, Zdenek - Koukalová, Renata - Křen, Leoš - Moulis, Mojmír - Krejčí, Marta - Mayer, Jiří
PY  - 2013
TI  - Salvage lenalidomide in four rare oncological diseases
JF  - Tumori
VL  - 99
IS  - 5
SP  - "e251"-"e256"
EP  - "e251"-"e256"
PB  - PENSIERO SCIENTIFICO EDITOR
SN  - 03008916
KW  - Langerhans cell histiocytosis
KW  - Erdheim-Chester disease
KW  - angiomatosis
KW  - Castleman disease
UR  - http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326
N2  - In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.
ER  -

SZTURZ, Petr, Zdeněk ADAM, Zdenek REHAK, Renata KOUKALOVÁ, Leoš KŘEN, Mojmír MOULIS, Marta KREJČÍ and Jiří MAYER. Salvage lenalidomide in four rare oncological diseases. \textit{Tumori}. Roma: PENSIERO SCIENTIFICO EDITOR, 2013, vol.~99, No~5, p.~''e251''-''e256'', 6 pp. ISSN~0300-8916. Available from: https://dx.doi.org/10.1700/1377.15326.

Detailed Information on Publication Record